News

Wellcome Trust invests a £200m VC
Enlarge image

FundingUK

Wellcome Trust invests a £200m VC

04.01.2013 - The Wellcome Trust’s new venture capital unit Syncona Partners LLC pours £200m into early stage healthcare start ups.

The world’s second largest charity plans to invest between £1m-£20m in each of its future portfolio companies as announced last spring. According to Wellcome's annual report last month, Syncona has already made one investment. The directly owned and managed investment firm combines the trust’s experience in the health and biotechnology sectors with its investment expertise. While Syncona offers a new source of finance and guidance for healthcare businesses at an early stage of their development, the trust hopes to make some return on investment to fuel its pipeline of charitable projects.

“We expect to play our part in building successful businesses based upon innovation within the life science and health-care industry,” Syncona Chief Executive Officer Martin Murphy said in a statement. According to the Trust’s annual report, its role is becoming an increasingly global one. It disclosed that UK assets now account for a mere 6% of its £14.5bn investment portfolio, down from 13% in 2009 and 33% in 2006. Hence the portfolio “has hardly suffered from the underperformance of European assets in the financial crisis.” The influential investor has also cut its assets in Europe, with the proportion of its portfolio invested in the continent falling to 13% (2009: 22%; 2006: 48%). The charity said that it envisaged better returns from faster-growing nations in Asia and Latin America.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2013-01/wellcome-trust-invests-a-pound200m-vc.html

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EPIGENOMICS4.34 EUR11.57%
  • PAION2.86 EUR10.85%
  • STRATEC BIOMEDICAL41.92 EUR3.92%

FLOP

  • CYTOS0.15 CHF-6.25%
  • MAGFORCE5.40 EUR-6.09%
  • CO.DON2.70 EUR-5.26%

TOP

  • BIOFRONTERA2.84 EUR29.1%
  • EPIGENOMICS4.34 EUR13.3%
  • VITA 344.42 EUR7.5%

FLOP

  • MAGFORCE5.40 EUR-21.7%
  • CYTOS0.15 CHF-16.7%
  • CO.DON2.70 EUR-14.0%

TOP

  • SANTHERA89.00 CHF2318.5%
  • CO.DON2.70 EUR172.7%
  • PAION2.86 EUR83.3%

FLOP

  • CYTOS0.15 CHF-96.2%
  • THERAMETRICS0.07 CHF-46.2%
  • 4SC0.94 EUR-43.4%

No liability assumed, Date: 30.10.2014